具有低PSMA表达的治疗未经处理的前列腺癌患者中纤维母细胞活化蛋白靶向PET/CT成像。
Fibroblast Activation Protein-Targeted PET/CT Imaging in a Treatment-Naive Prostate Cancer Patient With Low PSMA Expression.
发表日期：2023 Sep 07
作者：
Xingyu Mu, Meng Li, Jingquan Huang, Zhenzhen Wang, Wei Fu
来源：
CLINICAL NUCLEAR MEDICINE
摘要：
前列腺特异性膜抗原（PSMA）PET/CT逐渐被接受用于前列腺癌（PCa）的影像学，包括最近在初期分期中的应用。本病例报告中，我们介绍了一位76岁的男性患者，他被新诊断出患有PCa。18F-PSMA-1007 PET/CT显示原发肿瘤和转移病灶中PSMA活性较低。然而，18F-FAPI-04 PET/CT显示在原发肿瘤、转移淋巴结和骨骼中有更活跃的病灶。随后的组织病理学检查证实了PCa的诊断。这些发现表明，18F-FAPI-04可能在未接受治疗的低PSMA表达的PCa患者评估中具有潜在的作用。版权所有© 2023 Wolters Kluwer Health，Inc. 保留所有权利。
Prostate-specific membrane antigen (PSMA) PET/CT has become increasingly accepted for imaging prostate cancer (PCa), including its recent use in primary staging. In this case report, we present the case of a 76-year-old man with newly diagnosed PCa. 18F-PSMA-1007 PET/CT showed minimal PSMA activity in the primary tumor and metastases. However, 18F-FAPI-04 PET/CT revealed more avid lesions in primary tumor, metastatic lymph nodes, and bones. Subsequent histopathologic examination confirmed the diagnosis of PCa. These findings suggest that 18F-FAPI-04 may have a potential role in the evaluation of PCa with low PSMA expression in treatment-naive patients.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.